NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy

Molecular Psychiatry

Volumn 18, Issue 7, 2013, Pages 834-842

  Quraishe, S ^a   Cowan, C M ^a   Mudher, A ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Alzheimer's disease; axonal transport; Drosophila; microtubules; NAP (davunetide)

Indexed keywords

DAVUNETIDE; GREEN FLUORESCENT PROTEIN; NAP; NEUROPEPTIDE Y; TAU PROTEIN; TUBULIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; CYTOSKELETON; DISEASE MODEL; DROSOPHILA MELANOGASTER; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VIVO STUDY; MICROTUBULE; MOTONEURON; NERVE DEGENERATION; NERVE FIBER TRANSPORT; NEUROFIBRILLARY TANGLE; NEUROMUSCULAR SYNAPSE; NEUROPATHY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SYNAPSE; TAUOPATHY; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

ANIMALS; AXONAL TRANSPORT; DISEASE MODELS, ANIMAL; DROSOPHILA; MICROTUBULES; MOTOR ACTIVITY; NEURONS; OLIGOPEPTIDES; PHOSPHORYLATION; SYNAPSES; TAU PROTEINS; TAUOPATHIES;

EID: 84879412186     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2013.32     Document Type: Article

References (45)

1. Bonda DJ, Lee HP, Lee HG, Friedlich AL, Perry G, Zhu X et al. Novel therapeutics for Alzheimer's disease: an update. Curr Opin Drug Discov Dev 2010; 13: 235-246.
2. Alonso AC, Zaidi T, Grundke-Iqbal I, Iqbal K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci USA 1994; 91: 5562-5566.
3. Lovestone S, Reynolds CH. The phosphorylation of tau: a critical stage in neuro-development and neurodegenerative processes. Neuroscience 1997; 78: 309-324.
4. Cowan CM, Bossing T, Page A, Shepherd D, Mudher A. Soluble hyper-phos-phorylated tau causes microtubule breakdown and functionally compromises normal tau in vivo. Acta Neuropathol 2010; 120: 593-604.
5. Chee FC, Mudher A, Cuttle MF, Newman TA, MacKay D, Lovestone S et al. Over-expression of tau results in defective synaptic transmission in Drosophila neuromuscular junctions. Neurobiol Dis 2005; 20: 918-928.
6. Mudher A, Shepherd D, Newman TA, Mildren P, Jukes JP, Squire A et al. GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry 2004; 9: 522-530.
7. Terry RD. The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J Neuropathol Exp Neurol 1996; 55: 1023-1025.
8. Cash AD, Aliev G, Siedlak SL, Nunomura A, Fujioka H, Zhu X et al. Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am J Pathol 2003; 162: 1623-1627.
9. Ishihara T, Hong M, Zhang B, Nakagawa Y, Lee MK, Trojanowski JQ et al. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 1999; 24: 751-762.
10. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992; 42(3 Pt 1): 631-639.
11. Ballatore C, Brunden KR, Trojanowski JQ, Lee VM, Smith 3rd AB, Huryn DM. Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies. Curr Top Medicinal Chem 2011; 11: 317-330.
12. Gozes I. Tau pathology and future therapeutics. Curr Alzheimer Res 2010; 7: 685-696.
13. Trojanowski JQ, Smith AB, Huryn D, Lee VM. Microtubule-stabilising drugs for therapy of Alzheimer's disease and other neurodegenerative disorders with axonal transport impairments. Exp Opin Pharmacother 2005; 6: 683-686.
14. Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci USA 2005; 102: 227-231.
15. Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 1999; 72: 1283-1293.
16. Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D et al. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev 2005; 11: 353-368.
17. Divinski I, Holtser-Cochav M, Vulih-Schultzman I, Steingart RA, Gozes I. Peptide neuroprotection through specific interaction with brain tubulin. J Neurochem 2006; 98: 973-984.
18. Leker RR, Teichner A, Grigoriadis N, Ovadia H, Brenneman DE, Fridkin M et al. NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. Stroke; J Cerebl Circ 2002; 33: 1085-1092.
19. Gozes I, Steingart RA, Spier AD. NAP mechanisms of neuroprotection. J Mol Neurosci 2004; 24: 67-72.
20. Shiryaev N, Jouroukhin Y, Giladi E, Polyzoidou E, Grigoriadis NC, Rosenmann H et al. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis 2009; 34: 381-388.
21. Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Waterhouse EG, Mattson MP et al. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci 2007; 31: 165-170.
22. Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2008; 325: 146-153.
23. Sinadinos C, Cowan CM, Wyttenbach A, Mudher A. Increased throughput assays of locomotor dysfunction in Drosophila larvae. J Neurosci Methods 2012; 203: 325-334.
24. Sinadinos C, Burbidge-King T, Soh D, Thompson LM, Marsh JL, Wyttenbach A et al. Live axonal transport disruption by mutant huntingtin fragments in Drosophila motor neuron axons. Neurobiol Dis 2009; 34: 389-395.
25. Lei P, Ayton S, Finkelstein DI, Spoerri L, Ciccotosto GD, Wright DK et al. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med 2012; 18: 291-295.
26. Michaelis ML, Dobrowsky RT, Li G. Tau neurofibrillary pathology and microtubule stability. J Mol Neurosci 2002; 19: 289-293.
27. Michaelis ML, Chen Y, Hill S, Reiff E, Georg G, Rice A et al. Amyloid peptide toxicity and microtubule-stabilizing drugs. J Mol Neurosci 2002; 19: 101-105.
28. Brunden KR, Yao Y, Potuzak JS, Ferrer NI, Ballatore C, James MJ et al. The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies. Pharmacol Res 2011; 63: 341-351.
29. Brunden KR, Zhang B, Carroll J, Yao Y, Potuzak JS, Hogan AM et al. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neurosci 2010; 30: 13861-13866.
30. Gozes I, Divinski I. NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. Curr Alzheimer Res 2007; 4: 507-509.
31. Barten DM, Fanara P, Andorfer C, Hoque N, Wong PY, Husted KH et al. Hyper-dynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027. J Neurosci 2012; 32: 7137-7145
32. Davunetide (NAP) and D-NAP (AL-408) protect against tau hyperphosphorylation in a model of ALS: implications for axonal transport. Neuroscience Meeting Planner. Society for Neuroscience: New Orleans, LA, USA, 2012, abstract 242.05/E23.
33. Smith-Swintosky VL, Gozes I, Brenneman DE, D'Andrea MR, Plata-Salaman CR. Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures. J Mol Neurosci 2005; 25: 225-238.
34. Idan-Feldman A, Schirer Y, Polyzoidou E, Touloumi O, Lagoudaki R, Grigoriadis NC et al. Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model. Neurobiol Dis 2011; 44: 327-339.
35. Pascual M, Guerri C. The peptide NAP promotes neuronal growth and differentiation through extracellular signal-regulated protein kinase and Akt pathways, and protects neurons co-cultured with astrocytes damaged by ethanol. J Neurochem 2007; 103: 557-568.
36. Divinski I, Mittelman L, Gozes I. A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem 2004; 279: 28531-28538.
37. Oz S, Ivashko-Pachima Y, Gozes I. The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities. PloS One 2012; 7: e51458.
38. Sudo H, Baas PW. Strategies for diminishing katanin-based loss of microtubules in tauopathic neurodegenerative diseases. Hum Mol Genet 2011; 20: 763-778.
39. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010; 9: 702-716.
40. Zhang B, Carroll J, Trojanowski JQ, Yao Y, Iba M, Potuzak JS et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci 2012; 32: 3601-3611.
41. Beni-Adani L, Gozes I, Cohen Y, Assaf Y, Steingart RA, Brenneman DE et al. A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice. J Pharmacol Exp Ther 2001; 296: 57-63.
42. Rotstein M, Bassan H, Kariv N, Speiser Z, Harel S, Gozes I. NAP enhances neurodevelopment of newborn apolipoprotein E-deficient mice subjected to hypoxia. J Pharmacol Exp Ther 2006; 319: 332-339.
43. Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z et al. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperpho-sphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther 2007; 323: 438-449.
44. Jehle T, Dimitriu C, Auer S, Knoth R, Vidal-Sanz M, Gozes I et al. The neuropeptide NAP provides neuroprotection against retinal ganglion cell damage after retinal ischemia and optic nerve crush. Graefe's archive for clinical and experimental ophthalmology Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2008; 246: 1255-1263.
45. Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I. Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatric Disease Treatment 2012; 8: 85-93.